FDA Brief

Warning letters Food

FDA warning letter to

PYRLess Group, LLC dba Dr. Fitt

High riskIssued Jan 25, 2021Posted Mar 23, 2021Center for Food Safety and Applied Nutrition

FDA and FTC warned PYRLess Group (Dr. Fitt) for selling vitamin and iodine supplements claimed to prevent or treat COVID-19 without approval.

What happened

FDA and FTC reviewed the company's websites drfitt.com and drfittinfo.com on various dates since February 3, 2021 and February 10, 2021, and also reviewed its Facebook pages and a July 26, 2020 YouTube video. The review found the company offering Buffered C Powder, Get Well 2 Day Vit A, Get Well 2 Day Vit D3, Robynzyme and OMG Cell Protek with statements that these products mitigate, prevent, treat or cure COVID-19. FDA noted it had already sent the related firm Dr. Fitt Intelligent Designs, LLC an advisory letter on November 7, 2018 about disease claims, and that the websites still make such claims.

What FDA found

  1. The products are unapproved new drugs because they are sold with claims to prevent or treat COVID-19 and FDA has not approved them for that use.

    Section 505(a) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(a)
  2. The products are misbranded drugs because their labeling carries claims that are false or misleading.

    Section 502 of the FD&C Act, 21 U.S.C. § 352
  3. Shipping these products across state lines is prohibited.

    Sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. The company advertises that its products prevent, treat or cure disease without competent and reliable scientific evidence, which the FTC Act forbids.

    FTC Act, 15 U.S.C. 41 et seq.
  5. Deceptive claims about treating, curing, preventing or mitigating COVID-19 can bring a civil penalty of up to $43,792 per violation.

    COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260

What FDA wants

FDA asks the company to immediately stop selling the unapproved products and to review its websites, labels and promotional materials so they do not claim the products are safe or effective for COVID-19. Within 48 hours the company must email FDA describing the steps taken, and separately email the FTC with the actions taken to address its concerns.

Who should pay attention

  • supplement brands that make immunity, antiviral or respiratory claims
  • retailers and online marketplaces carrying COVID-19 related supplements
  • practitioners and influencers whose names or likenesses are licensed to supplement sellers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk